Abstract 5287
Background
Nivolumab, an anti-PD-1 antibody showed durable responses and long-term survival in patients with hepatocellular carcinoma (HCC) and was approved by FDA as 2nd line treatment after sorafenib treatment in 2017. We present real-world experience with nivolumab in HCC.
Methods
We retrospectively reviewed the medical records of HCC patients who had nivolumab treatment at Samsung Medical Center. Nivolumab treatment was given every two weeks until progression or intolerable toxicity. Response evaluation was done based on RECIST v1.1.
Results
A total of 76 patients were treated with nivolumab between March 2017 and May 2018. The median age was 60 years (range; 30-83 years) and 86% were male patients. The cohorts included 56 patients with hepatitis B viral infection, 7 with hepatitis C viral infection and 19 without viral infection. Most of patients (96.0%) were ECOG performance statue 0 or 1 and patients with Child-Pugh A were 59 (77.6%). 70 patients (92.1%) had previous sorafenib therapy and 8 patients received nivolumab as 3rd or more line (10.5%). There were three patients with previous history of liver transplantation. With median follow-up duration of 15 weeks (range, 5-39), the median treatment cycle was 4 (range,1-26). 17 patients (22.4%) received standard dose of 3mg/kg, whereas 59 patients (77.6%) received less than 3mg/kg of nivolumab. Partial response was observed in 6 patients (ORR 7.9%) and they all are on nivolumab therapy for 4-13 months. Disease control rate was 39.5%. The most common adverse events (AEs) were anorexia(15.6%) and puritus(15.8%)., nausea (13.1%), liver dysfunction (21%) and fatigue(7.9%). However, these were almost grade 1 or 2 except for two cases of grade 3 liver dysfunction and grade 3 diabetes. There was no HBV reactivation observed.
Conclusions
Compared to phase I/II study of nivolumab (CheckMate 040), our real-world data showed lesser ORR and DCR. Move advanced disease status, liver dysfunction and short follow-up duration might explain it. However, nivolumab showed a manageable safety profile even in transplanted patients.
Clinical trial identification
Legal entity responsible for the study
Samsung Medical Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract